{"id":29740,"date":"2026-07-02T11:00:00","date_gmt":"2026-07-02T09:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=59df0414cb707b3dcde4f38c78697071"},"modified":"2026-07-02T11:00:00","modified_gmt":"2026-07-02T09:00:00","slug":"brenus-pharma-strengthens-its-governance-with-designation-of-a-new-president-and-appointment-of-former-novo-nordisk-evp-as-independent-member","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=29740","title":{"rendered":"Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member"},"content":{"rendered":"

LYON, France--(BUSINESS WIRE)--#Biotech<\/a>--Brenus Pharma, today announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE<\/b>, as President & Chairman of the board, succeeding co-founder Jacques GARDETTE<\/b>, who will remain an active board member. Eric brings extensive experience in healthcare innovation and value creation, having notably led BIOCORP<\/a> through its development and acquisition by Novo Nordisk. Brenus also appoints Camilla SYLVEST<\/b><\/a>, as a second independent director, following the earlier addition of Diala EZZEDDINE<\/b><\/a> a seasoned US-based biotech executive and entrepreneur.<\/p><\/a><\/a>

\nCamilla SYLVEST<\/b><\/a> is an experienced pharmaceutical executive and global business leader, having spent nearly three decades at Novo Nordisk A\/S<\/a>, where she most recently served as Executive Vice President for Global Commercial Strategy, Corporate Communication and Sustainability. She currently serves on the Boards of Argenx SE<\/a>, Getinge AB<\/a>, and Zealand Pharma<\/a> A\/S, and has previously served on the Board of Danish Crown A\/S<\/a> and as vice-chair at World Diabetes Foundation.<\/a><\/p>

\n\"Eric's proven track record, combined with Diala's and Camilla's expertise, positions us well to execute our ambitious goals for Brenus. I also want to thank Jacques GARDETTE for his foundational vision and unwavering support of Brenus,\u201d<\/b> said Paul BRAVETTI, CEO of Brenus Pharma.<\/p>

\n\u201cI am honored to chair a Board with this caliber of experts. Diala and Camilla provide strategic guidance towards our goal to continue building a leading biotech company,\u201d<\/b> said Eric DESSERTENNE, Chairman of the Board & President of Brenus Pharma.<\/p>

\n\u201cWhat attracted me to Brenus is the elegance of the company\u2019s science and the accumulating clinical evidence of its potential to transform the treatment of solid tumors,\"<\/b> said Camilla SYLVEST<\/b>. \u201cI look forward to working with the team.\u201d<\/b><\/p>

\nAbout Brenus Pharma<\/b><\/p>

\nBrenus Pharma, clinical stage company, develops an off-the-shelf platform advancing novel modalities in immuno-oncology. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response adapting to tumor evolution in hard-to-treat solid tumors, where current therapies fall short.<\/p>

\nwww.brenus-pharma.com<\/a><\/p> Contacts<\/b>

\ncontact@brenus-pharma.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LYON, France–(BUSINESS WIRE)–#Biotech–Brenus Pharma, today announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE, as President & Chairman of the board, succeeding co-founder Jacques GARDETTE, who will remain…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-29740","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29740"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29740\/revisions"}],"predecessor-version":[{"id":29741,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/29740\/revisions\/29741"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}